- Symeres has appointed Henning Steinhagen as Chief Executive Officer as part of a planned leadership transition.
- The company said the appointment supports its next phase of growth as a transatlantic CRDMO operating across nine global sites with more than 500 scientists.
Symeres has appointed Henning Steinhagen as Chief Executive Officer, succeeding Guillaume Jetten in a planned leadership transition aimed at supporting the company’s next phase of growth.
The company stated that Jetten played a central role in strengthening Symeres’ operational and scientific capabilities during a period of expansion and transformation. Symeres has grown through a combination of organic expansion and targeted acquisitions into a transatlantic contract research, development, and manufacturing organization (CRDMO) with more than 500 scientists across nine global sites.
Dr. Steinhagen brings more than 25 years of experience across the pharmaceutical, biotechnology, and CRO/CDMO sectors. He joins Symeres from Lario Therapeutics, where he served as CEO and co-founder, and previously held leadership positions at Aptuit, Grünenthal, Sanofi-Aventis, and Bayer Pharma.
According to the company, Steinhagen will focus on advancing Symeres’ “One Symeres” integrated platform strategy, supporting partnerships across biotech and pharmaceutical companies from drug discovery through development. His background includes expertise in chemistry, biology, ADME-tox, and CMC-related operations.
“With strong foundations in place, the opportunity ahead is to fully realize and unlock the power of integrated services across chemistry and biology.” The company stated that the leadership transition is intended to build on recent progress integrating teams, capabilities, and services across its global network.
Dr. Steinhagen
